Investor Presentaiton

Tumor Volume (mm³) SAR-bisPSMA: Pre-clinical data SAR-bisPSMA is ideally suited for a theranostic radiopharmaceutical % IA/g High uptake and retention in tumour 120- ༔ ༔ 30\ 20- 10- Blood Lungs Heart Liver Kidneys Muscle Spleen Tumour Preclinical biodistribution study demonstrating high uptake and retention of I 64CU SAR-bisPSMA in tumours with rapid clearance from non-target organs Zia et al., 2019. Ang.Chem hr 4 hr 24 hrs Significant anti-tumour effect 1200 1000- 800- 600- 400- 200 0- 0 -Vehicle CLARITY 2014 M Rapid kidney clearance of non-bound activity SUV 10 SUV 10 Preclinical efficacy study with increasing activity of 67CU SAR- bisPSMA (colours) demonstrating dose response 10 20 30 40 50 60 70 80 McInnes et al., 2020. JNM Time (d) 7.5 MBq Cu-CuSARbisPSMA 15 MBq Cu-CuSARbisPSMA 30 MBq Cu-CuSARbis PSMA ■15 (1) 15 (15) MB Cu-CuSARbisPSMA 1 hr 24 hr Tumour targeting and superior retention over 24 hours PET images showing 64CU SAR- bisPSMA targeting to tumours over time and rapid kidney clearance 'bisPSMA' The term "bis" is used to denote the presence of two identical but separate complex groups in one molecule High uptake and retention in tumour compared to Pluvicto™M (PSMA-617) 35% % Injected Activity/g tumour 30% 25% 20% 15% 10% 5% 0% T= 1h T= 24h T= 1h T= 24h PSMA-617 SAR-bisPSMA From Benesova et al 2015 From Zia et al 2019 12

View entire presentation